Which asthma drugs, dosages work best for African Americans?

February 19, 2014

The University of Illinois at Chicago has received funding from the National Institutes of Health to determine what combination and dosages of asthma medications works best to manage asthma in African Americans, who suffer much higher rates of serious asthma attacks, hospitalizations and asthma-related deaths than do white patients.

"We know that African Americans tend to have more difficulty with asthma compared to other groups," says Dr. Jerry Krishnan, associate vice president for and population health sciences at the University of Illinois Hospital & Health Sciences System and principal investigator at the UIC study site. "Part of the reason is that we don't know which medications and in what combinations work best in African Americans to treat and prevent asthma symptoms. This study will help give us that information."

UIC is one of the 30 sites in 14 states taking part in the clinical trial Best African American Response to Asthma Drugs, or BARD. The trial will examine the effectiveness of different doses of inhaled corticosteroids used with or without the addition of a long-acting beta agonist in 500 African Americans age 5 and older.

Inhaled corticosteroids reduce inflammation and help control asthma in the long term, while long-acting beta agonists relax tight airway muscles. This study will compare multiple combinations of these medications and different dosing regimens to determine which works best for African American patients. The trial will also evaluate how genes may affect treatment response.

According to the U.S. Department of Health and Human Services, African Americans are 20 percent more likely to have asthma than non-Hispanic whites. Chicago has a high incidence of asthma because of its large African American population.

"We're excited to be a part of this study because it aligns so well with the mission of our health system to reduce health disparities," said Krishnan, who is professor of medicine in the UIC College of Medicine. "Studies like BARD provide health data that will help us improve the lives of understudied populations that carry a disproportionate burden of disease.

Explore further: Rare genetic variations may account for severe reaction to LABA drugs in some people

Related Stories

1990s trial gave early danger signs for asthma drugs

November 25, 2012

The troubled history of asthma drugs known as long-acting beta-agonists goes back to the 1990s when a large clinical trial in Great Britain of the GlaxoSmithKline drug Serevent produced disturbing results.

Recommended for you

Scientists reveal cellular clockwork underlying inflammation

August 27, 2015

Researchers at the Virginia Bioinformatics Institute at Virginia Tech have uncovered key cellular functions that help regulate inflammation—a discovery that could have important implications for the treatment of allergies, ...

New research finds ozone in smog may cause asthma

September 7, 2015

It's completely invisible, but the distinctive smell of electrical discharge after photocopying is a tell-tale sign of ozone in the air. Ozone is a component of what we refer to as 'smog' and on hot sunny days, in cities ...

Severe asthma fails to respond to mainstay treatment

June 29, 2015

The immune response that occurs in patients with severe asthma is markedly different than what occurs in milder forms of the lung condition, according to researchers from the University of Pittsburgh School of Medicine. Those ...

New hope for patients with chronic wounds

June 29, 2015

Most wounds clear up by themselves, but some fail to heal and become chronic. An international team of researchers led from Karolinska Institutet, now unveil the important role of so-called microRNAs in regulating skin wound ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.